Firm to present flagship innovative formulation platform, NanoM™, at TechConnect World Innovation Conference, May 23 and 24, 2016 in National Harbor, MD, USA.

BEDFORD, MASSACHUSETTS, USA, May 16, 2016 /EINPresswire.com/ -- Integral BioSystems LLC, Boston area CRO specializing in ophthalmological pharmaceutical formulation development, will be displaying at the TechConnect World Innovation Conference & Expo on May 23 and 24, 2016 at the Gaylord National Resort and Convention Center, 201 Waterfront Street, National Harbor, Maryland 20745, USA.

The focus of the material to be presented by inventor and 23 year industry veteran Dr. Shikha P. Barman will be the drug delivery platform NanoM™. This platform is being developed as a biocompatible, biodegradable, mucoadhesive insert to deliver medications to treat disorders of the ocular surface, tissues surrounding the ocular surface and the anterior chamber. These disorders include uveitis, glaucoma, inflammation post-cataract surgery and ocular surface infections. The insert can be developed to deliver medications over days to weeks, depending upon the clinical need.

One indication addressed by NanoM™ is the treatment of glaucoma by sustained administration of an anti- glaucoma medication. This technology offers considerable advantages over competitor technologies, in that it is self-administered and does not require clinician intervention. Once competely developed, this technology would be the first self-administered sustained release delivery system. Currently, glaucoma medications are delivered by eye-drops; 95% of each eye-drop is lost through inefficient absorption and naso-lacrimal drainage.

This technology has already gained considerable traction with US and international companies, as well as the NIH, which has awarded a Phase I SBIR Grant to further the product’s development. Integral has filed requisite patent applications and is actively developing the platform further to include multiple routes and multiple indications. In the words of Integral BioSystems’ CEO, Shikha P. Barman, Ph.D., “this technology has the potential to achieve therapeutic effect by efficient and effective tissue absorption of a lower dose, thus eliminating side effects in ophthalmic medications”.

Integral BioSystems is seeking investment with interested parties to develop the platform. A new company is planned as part of a developmental partnership, utilizing Integral BioSystems’ facilities and expertise in formulation and analytical development to develop and ready each product for the platform.

About Integral BioSystems
Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

The Company has developed numerous dosage forms for ophthalmic applications. Integral BioSystems has a translational approach to drug development, customizing delivery systems to achieve the biologically effective objectives of the therapy. Dosage forms are customized to achieve sustained release or targeted, tissue-focused delivery or fast-release/instant delivery, depending upon the desired product attributes.

Dave Karasic
Integral BioSystems, LLC
617-820-8483
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.